Custom-Made vaccine takes on kidney cancer in early trial
NCT ID NCT02950766
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a personalized vaccine made from unique markers in a person's kidney tumor. The vaccine is given along with two immune-boosting drugs (Poly-ICLC and ipilimumab) to see if it is safe and can train the immune system to fight the cancer. The trial includes 19 people with high-risk kidney cancer that has been surgically removed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Could an ALS drug clear the fog of chemo brain?
- Drug cocktail aims to shrink kidney tumors before surgery and prevent return
- Smart bomb for kidney cancer: imaging and radiation combo targets tough tumors
- Ancient Mind-Body practice tested as fatigue fighter for men after cancer